<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333645</url>
  </required_header>
  <id_info>
    <org_study_id>GESITRA-01</org_study_id>
    <secondary_id>03-0409 (Spanish Drug Agency)</secondary_id>
    <nct_id>NCT00333645</nct_id>
  </id_info>
  <brief_title>Prophylaxis With Caspofungin in High-Risk Liver Transplantation</brief_title>
  <official_title>Prophylaxis With Caspofungin for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Estudio de Infecciones en Transplantados</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo de Estudio de Infecciones en Transplantados</source>
  <brief_summary>
    <textblock>
      This is a non-comparative, open, multisite prospective estimation study to evaluate the
      efficacy and safety of caspofungin in the prophylactic treatment of adults who have received
      an orthotopic liver transplant and are at high risk of developing an invasive fungal
      infection. It is expected that the proportion of high-risk liver transplant recipients who
      develop a documented (proven or probable per European Organization for Research and Treatment
      of Cancer/Mycoses Study Group [EORTC/MSG] modified criteria) invasive fungal infection during
      the first 100 days after the onset of prophylaxis with caspofungin will be lower than 15%. It
      is also expected that the incidence of serious drug-related adverse events will be less than
      25%.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2003</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of breakthrough proven/probable invasive fungal infection by day +100</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of breakthrough proven/probable invasive aspergillosis by day +100</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of study therapy due to a drug-related adverse event</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related serious adverse event(s)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related adverse event(s)</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Fungal Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Patient has received an orthotopic liver transplantation

          -  Patient meets criteria, as defined per protocol, for being considered at high risk of
             developing an invasive fungal infection post-liver transplantation

          -  For women of childbearing potential, patient must have a negative serum or urine
             pregnancy test

        Exclusion Criteria:

          -  Any systemic antifungal therapy (other than fluconazole for a maximum of 7 days)
             within 14 days of the administration of the study drug.

          -  Documented (proven/probable) or suspected (possible) invasive fungal infection at the
             time of enrollment.

          -  Abnormal laboratory values as defined per protocol.

          -  Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal.

          -  Patient not expected to survive at least 5 days.

          -  Patient is pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesus Fortun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Ramon y Cajal, Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesus Fortun, MD, PhD</last_name>
    <phone>+34-670-537460</phone>
    <email>fortun@mi.madritel.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>E-48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Montejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>E-08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joan Gavaldà, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>E-14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>E-18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Garrote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Juan Canalejo</name>
      <address>
        <city>La Coruña</city>
        <zip>E-15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro Llinares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>E-28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>E-28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jesus Fortun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>E-28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>E-28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafael San Juan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>E-29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cesar Aragon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>E-15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Evaristo Varo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>E-41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose-Miguel Cisneros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>E-46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marino Blanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Fortun J, Muñoz P, Cisneros JM, et al. Antifungal prophylaxis with caspofungin in high-risk liver transplant recipients: a noncomparative, open-label prospective clinical trial. Clinical Microbiology &amp; Infection 12 (suppl. 4): P684, 2006. [Abstract on an interim analysis performed on the first 15 patients enrolled in the study, presented as a poster at 2006 ECCMID meeting].</citation>
  </results_reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2006</study_first_submitted>
  <study_first_submitted_qc>June 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2006</study_first_posted>
  <last_update_submitted>April 12, 2007</last_update_submitted>
  <last_update_submitted_qc>April 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2007</last_update_posted>
  <keyword>Liver transplantation</keyword>
  <keyword>Invasive fungal infection</keyword>
  <keyword>Invasive aspergillosis</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Caspofungin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

